149 related articles for article (PubMed ID: 27901576)
21. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
22. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
Gonzalez-Angulo AM; Ferrer-Lozano J; Stemke-Hale K; Sahin A; Liu S; Barrera JA; Burgues O; Lluch AM; Chen H; Hortobagyi GN; Mills GB; Meric-Bernstam F
Mol Cancer Ther; 2011 Jun; 10(6):1093-101. PubMed ID: 21490305
[TBL] [Abstract][Full Text] [Related]
23. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
Harlé A; Lion M; Lozano N; Husson M; Harter V; Genin P; Merlin JL
Oncol Rep; 2013 Mar; 29(3):1043-52. PubMed ID: 23314198
[TBL] [Abstract][Full Text] [Related]
24. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
Saal LH; Holm K; Maurer M; Memeo L; Su T; Wang X; Yu JS; Malmström PO; Mansukhani M; Enoksson J; Hibshoosh H; Borg A; Parsons R
Cancer Res; 2005 Apr; 65(7):2554-9. PubMed ID: 15805248
[TBL] [Abstract][Full Text] [Related]
25. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
Ellis MJ; Lin L; Crowder R; Tao Y; Hoog J; Snider J; Davies S; DeSchryver K; Evans DB; Steinseifer J; Bandaru R; Liu W; Gardner H; Semiglazov V; Watson M; Hunt K; Olson J; Baselga J
Breast Cancer Res Treat; 2010 Jan; 119(2):379-90. PubMed ID: 19844788
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.
Adamczyk A; Niemiec J; Janecka A; Harazin-Lechowska A; Ambicka A; Grela-Wojewoda A; Domagała-Haduch M; Cedrych I; Majchrzyk K; Kruczak A; Ryś J; Jakubowicz J
Pol J Pathol; 2015 Jun; 66(2):133-41. PubMed ID: 26247526
[TBL] [Abstract][Full Text] [Related]
27. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
29. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
López-Knowles E; Segal CV; Gao Q; Garcia-Murillas I; Turner NC; Smith I; Martin LA; Dowsett M
Breast Cancer Res; 2014 Jun; 16(3):R68. PubMed ID: 24981670
[TBL] [Abstract][Full Text] [Related]
30. PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.
Deb S; Do H; Byrne D; Jene N; ; Dobrovic A; Fox SB
Breast Cancer Res; 2013; 15(4):R69. PubMed ID: 23971979
[TBL] [Abstract][Full Text] [Related]
31. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.
Abramson VG; Cooper Lloyd M; Ballinger T; Sanders ME; Du L; Lai D; Su Z; Mayer I; Levy M; LaFrance DR; Vnencak-Jones CL; Shyr Y; Dahlman KB; Pao W; Arteaga CL
Breast Cancer Res Treat; 2014 Jun; 145(2):389-99. PubMed ID: 24722917
[TBL] [Abstract][Full Text] [Related]
32. Detection of cancer DNA in plasma of patients with early-stage breast cancer.
Beaver JA; Jelovac D; Balukrishna S; Cochran R; Croessmann S; Zabransky DJ; Wong HY; Toro PV; Cidado J; Blair BG; Chu D; Burns T; Higgins MJ; Stearns V; Jacobs L; Habibi M; Lange J; Hurley PJ; Lauring J; VanDenBerg D; Kessler J; Jeter S; Samuels ML; Maar D; Cope L; Cimino-Mathews A; Argani P; Wolff AC; Park BH
Clin Cancer Res; 2014 May; 20(10):2643-2650. PubMed ID: 24504125
[TBL] [Abstract][Full Text] [Related]
33. Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
Wu G; Xing M; Mambo E; Huang X; Liu J; Guo Z; Chatterjee A; Goldenberg D; Gollin SM; Sukumar S; Trink B; Sidransky D
Breast Cancer Res; 2005; 7(5):R609-16. PubMed ID: 16168105
[TBL] [Abstract][Full Text] [Related]
34. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
Moynahan ME; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Ringeisen F; Hortobagyi GN; Baselga J; Chandarlapaty S
Br J Cancer; 2017 Mar; 116(6):726-730. PubMed ID: 28183140
[TBL] [Abstract][Full Text] [Related]
35. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
[TBL] [Abstract][Full Text] [Related]
36. Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai.
Wang YL; Dai X; Li YD; Cheng RX; Deng B; Geng XX; Zhang HJ
Genet Mol Res; 2015 Nov; 14(4):14840-6. PubMed ID: 26600545
[TBL] [Abstract][Full Text] [Related]
37. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.
Hsieh LL; Er TK; Chen CC; Hsieh JS; Chang JG; Liu TC
Clin Chim Acta; 2012 Oct; 413(19-20):1605-11. PubMed ID: 22579930
[TBL] [Abstract][Full Text] [Related]
38. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
Kalinsky K; Heguy A; Bhanot UK; Patil S; Moynahan ME
Breast Cancer Res Treat; 2011 Sep; 129(2):635-43. PubMed ID: 21617917
[TBL] [Abstract][Full Text] [Related]
39. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
40. Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese.
Liang X; Lau QC; Salto-Tellez M; Putti TC; Loh M; Sukumar S
Cancer Biol Ther; 2006 May; 5(5):544-8. PubMed ID: 16582596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]